A recent report published by Infinium Global Research on the peptide therapeutics market provides in-depth analysis of segments and sub-segments in the global as well as regional peptide therapeutics market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional peptide therapeutics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global peptide therapeutics market. According to the report, the global peptide therapeutics market is projected to grow at a CAGR of 10% over the forecast period of 2022-2028. The revenue generated by the market was USD approximately 37 billion in 2021 and is expected to reach approximately USD 64 billion in 2028.

Market Insight

The peptide therapeutics market is projected to register a 10% CAGR during the forecast period. Peptides are short chains of amino acids linked by a peptide bond; they perform many roles within the cell including signaling and anti-infective. The suitability of the peptide for therapeutic use depends on the sequence, whether it is based on those peptides that are naturally produced by the body, similar to those naturally produced, or a sequence novel to the body. The key factors driving the market growth are the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics. According to the World Health Organization (WHO), chronic diseases, such as cancer, cardiovascular diseases, and diabetes, are the leading causes of death and disability worldwide. Furthermore, the consistently increasing cancer populations across the globe with technological advancements are likely to uncover growth opportunities throughout the forecasted period.

Peptides are being made and repurposed as therapeutics for the treatment of covid-19. Researchers are still searching for the compounds that will either stop the replication process of SARS-CoV-2 or treat conditions caused by the infection, worldwide. On February 21, 2020, the FDA updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less. As of May 2020, there were 21 peptide drugs for the treatment of COVID-19, including 15 synthetic peptides in development for the treatment of acute respiratory distress syndrome (ARDS) and other respiratory illnesses caused by SARS-Cov-2 infection. Therefore, in the conclusion, COVID-19 may have a positive impact on the peptide therapeutics market as peptide drugs are being considered as a treatment option for dealing with COVID-19. Nevertheless, the current applications of peptide therapeutics in oncology, metabolic disorders, etc., have been disrupted due to a shortage of drugs and supply chain issues, along with the slow progress of clinical trials related to non-COVID-19 therapeutics.  Infinium Global Research's recent report on the “Peptides therapeutics market" offers an ample outline of the factors responsible for the growth of the market. This Peptides therapeutics market report includes all the details such as all the new recent developments, import-export analysis, production analysis, strategic market growth product launches, and much other information.

The global peptide therapeutics market has experienced progressive growth over the past few years. Growth in the global market is highly credible to the rising prevalence of metabolic disorders coupled with an increasing pool of cancer patients. Moreover, recent technological advancements have reduced the production cost of peptide drugs thereby fuelling growth remarkably in the global market. Rising research activities and the development pipeline of peptide drugs are anticipated to provide numerous growth opportunities over the forecast period. Although driven by the aforementioned factors, growth in this market is hampered by the complexity of peptide therapies may limit the manufacturing of peptide drugs. Furthermore, the consistently increasing cancer population across the globe with technological advancements is likely to uncover growth opportunities throughout the forecasted period. Additionally, the increasing incidence of metabolic disorders across the globe will also be expected to create numerous growth opportunities in the forthcoming years.

The report provides a regional outlook covering geographies such as North America, Europe, Asia-Pacific, and the Rest of the World. North America holds the command over the global peptide therapeutics market and is expected to dominate the overall market during the forecast period. The market growth is due to factors such as a rise in awareness levels relating to peptide therapeutic products, the increasing necessity for diagnostics in cancer and other diseases, and the growing biotechnology industry. The region is anticipated to retain its dominance throughout the forecasted period driven by advanced healthcare infrastructure in this region. Moreover, the presence of established players in this region contributed significantly to the regional growth. Following North America, Europe stands second in the global market including major markets such as Germany, Spain, Netherland, and the UK. The emergence of pharmaceutical and biotech companies, massive investment in healthcare startups, and rising initiatives from government authorities to develop cost-effective and safe drugs are some of the important market drivers in this region. On the other hand, Asia Pacific anticipated emerging as the most lucrative region by growing at the highest CAGR in the years to come. This is due sophisticated healthcare infrastructure in this region as well as the growing cancer population along with increasing incidences of metabolic disorders.

Segment Covered

The report on the global peptide therapeutics market covers segments such as marketing type, application, and route of administration. On the basis of marketing type, the sub-markets include generic and branded. On the basis of application, the sub-markets include gastrointestinal disorders, neurological disorders, metabolic disorders, cancer, and other applications. On the basis of route of administration, the sub-markets include parenteral, oral, and other routes of administration.

Companies Profiled:

The report provides profiles of the companies in the market such as Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Sanofi SA, Pfizer Inc, Novartis AG, GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., Eli Lilly, and Co., Bachem Holding AG, and Amgen Inc.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the peptide therapeutics market. Moreover, the study highlights current market trends and provides forecast from 2022-2028. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.